Compare Keysight Technologies Inc (KEYS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Summit Therapeutics Inc — how do they compare? Keysight Technologies Inc trades at $326.9 (market cap $53.68B), while Summit Therapeutics Inc trades at $14.41 (market cap $10.48B). The key difference: Keysight Technologies Inc is far larger — about 5.1× Summit Therapeutics Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| KEYS | SMMT | |
|---|---|---|
Market Cap | $53.68B | $10.48B |
Sector | Technology | Health |
52-Week High | $373.34 | $29.32 |
52-Week Low | $158.51 | $13.05 |
Enterprise Value | $54.03B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $313.97, down 0.61% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong profitability with a 17.31% net margin and has secured strategic partnerships, including a European Space Agency contract for 5G network development announced July 15, 2026. Analyst consensus remains strongly bullish with an $396.56 price target, though valuation multiples appear elevated with a P/E of 50.87.
KEYS presents a growth opportunity driven by AI and 5G testing demand, but faces risks from high valuation and volatile cash flows. The stock's near-term direction hinges on Q2 2026 earnings versus the $2.46 EPS estimate, with support at $309 critical for maintaining bullish technical structure.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
